Healios KK Ord Shs HLOSF

Healthcare Biotechnology

Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.

PINL:HLOSF - Post by User

Healios KK Ord Shs

<< Previous

Bullboard Posts

Next >>

Post by The300on Aug 11, 2011 5:35pm

289 Views

Post# 18933124

Hudbay

Hudbay recently released a webcast presentation (Aug 10th) for their second quarter results where they also discuss their prospects.

https://investor.shareholder.com/common/download/download.cfm?companyid=HBM&fileid=490743&filekey=1d89b30a-1336-4dbf-afe2-5640fdecfa86&filename=Hudbay_Q2Presentation_Aug9_FINAL.pdf

Unfortunately no mention of Cold/Lost or Halo Resources. VMS Ventures joint venture is mentioned.

I'm guessing that Cold/Lost production is a no-go. Shareprice seems to support that assertion.

Unless management can pull a rabbit out of a hat, any shareprice appreciation will hinge on the next drill program this winter.

As always, the above is IMHO

The 300

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec